Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.850 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,377
Open 1.850
Bid (Size) 1.800 (2,500)
Ask (Size) 1.910 (1,900)
Prev. Close 1.850
Today's Range 1.850 - 1.850
52wk Range 1.070 - 6.809
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
From Pomerantz LLP
Via GlobeNewswire
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill

Performance

YTD
-60.4%
-60.4%
1 Month
-62.9%
-62.9%
3 Month
-65.0%
-65.0%
6 Month
-63.1%
-63.1%
1 Year
-72.3%
-72.3%

More News

Read More
These stocks have an unusual volume in today's session ↗
Via Chartmill
News headline image
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – ALDX
From The Rosen Law Firm, P.A.
Via Business Wire
Top movers in Thursday's session ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Gapping stocks in Tuesday's session ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Why Did ALDX Stock Tank 75% In Pre-Market Today? ↗
Via Stocktwits
News headline image
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Nasdaq, S&P 500 Futures Rise As Nvidia GTC, Iran Tensions, Fed Meet Loom: Why META, MU, SOC, ALDX Are Also In Focus Today ↗
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait ↗
Via Stocktwits
News headline image
SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold Conviction ↗
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million Buy ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Aldeyra Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
News headline image
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? ↗
Via Stocktwits
News headline image
Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics Announces Expansion of RASP Platform to Include Central Nervous System Diseases and Provides Updates on Reproxalap at Research & Development Webcast
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra Therapeutics to Host Research & Development Update Webcast Event Scheduled for Thursday, November 13 at 8:00 a.m. ET
From Aldeyra Therapeutics, Inc.
Via Business Wire
News headline image
Aldeyra’s Experimental Drug Shows Promising Results In Mid-Stage Alcohol Hepatitis Trial ↗
Via Stocktwits
News headline image
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
From Aldeyra Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
The current price of Aldeyra Therapeutics, Inc. - Common Stock is 1.850
When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 03/25/26 04:00 PM ET
What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 108.37M
How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
Aldeyra Therapeutics, Inc. - Common Stock has 108M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.